This is not the most recent version of the article. View current version (25 JAN 2006)

Intervention Review

You have free access to this content

Influenza vaccine for patients with chronic obstructive pulmonary disease

  1. PJ Poole,
  2. E Chacko,
  3. RWB Wood-Baker,
  4. CJ Cates

Editorial Group: Cochrane Airways Group

Published Online: 24 JUL 2000

DOI: 10.1002/14651858.CD002733


How to Cite

Poole PJ, Chacko E, Wood-Baker RWB, Cates CJ. Influenza vaccine for patients with chronic obstructive pulmonary disease. The Cochrane Database of Systematic Reviews 2000, Issue 3. Art. No.: CD002733. DOI: 10.1002/14651858.CD002733.

Author Information

*Dr Phillippa Poole, Associate Professor in Medicine, University of Auckland, Private Bag 92019, Auckland, NEW ZEALAND. p.poole@auckland.ac.nz.

Publication History

  1. Published Online: 24 JUL 2000

SEARCH

This is not the most recent version of the article. View current version (25 JAN 2006)

 
Comparison 01. Influenza vaccination versus placebo

Outcome titleNo. of studiesNo. of participantsStatistical methodEffect size

01 Total exacerbations per patient
 FigureFigure 1. 01 Total exacerbations per patient
155Weighted Mean Difference (Fixed) 95% CI-0.45 [-0.75, -0.15]

02 Early exacerbations per patient
 FigureFigure 2. 02 Early exacerbations per patient
155Weighted Mean Difference (Fixed) 95% CI0.01 [-0.28, 0.30]

03 Late exacerbations per patient
 FigureFigure 3. 03 Late exacerbations per patient
155Weighted Mean Difference (Fixed) 95% CI-0.44 [-0.68, -0.20]

04 Patients with exacerbations
 FigureFigure 4. 04 Patients with exacerbations
297Peto Odds Ratio 95% CI1.06 [0.48, 2.33]

05 Patients with early exacerbations
 FigureFigure 5. 05 Patients with early exacerbations
155Peto Odds Ratio 95% CI1.38 [0.44, 4.30]

06 Patients with late exacerbations
 FigureFigure 6. 06 Patients with late exacerbations
155Peto Odds Ratio 95% CI0.13 [0.04, 0.45]

07 Hospitalisations
 FigureFigure 7. 07 Hospitalisations
155Peto Odds Ratio 95% CI0.14 [0.01, 2.39]

08 Mortality
 FigureFigure 8. 08 Mortality
155Peto Odds Ratio 95% CI0.15 [0.00, 7.61]

09 Overall change in lung function (FEV1 in litres)
 FigureFigure 9. 09 Overall change in lung function (FEV1 in litres)
155Weighted Mean Difference (Fixed) 95% CI-0.02 [-0.12, 0.08]

10 Change in early lung function (FEV1 in litres)
 FigureFigure 10. 10 Change in early lung function (FEV1 in litres)
155Weighted Mean Difference (Fixed) 95% CI-0.01 [-0.09, 0.07]

11 Total adverse effects
 FigureFigure 11. 11 Total adverse effects
00Peto Odds Ratio 95% CINot estimable

12 Patients with early breathlessness
 FigureFigure 12. 12 Patients with early breathlessness
144Peto Odds Ratio 95% CI1.28 [0.38, 4.31]

13 Patients with early tightness
 FigureFigure 13. 13 Patients with early tightness
144Peto Odds Ratio 95% CI1.28 [0.38, 4.31]

14 Patients with early wheeze
 FigureFigure 14. 14 Patients with early wheeze
144Peto Odds Ratio 95% CI3.57 [1.10, 11.56]

15 Patients with early cough
 FigureFigure 15. 15 Patients with early cough
144Peto Odds Ratio 95% CI4.09 [0.74, 22.49]

16 Patients with early sputum production
 FigureFigure 16. 16 Patients with early sputum production
144Peto Odds Ratio 95% CI2.03 [0.48, 8.66]

 
Comparison 02. Inactivated/ Live versus Inactivated/Placebo

Outcome titleNo. of studiesNo. of participantsStatistical methodEffect size

01 Total exacerbations per patient
 FigureFigure 17. 01 Total exacerbations per patient
129Weighted Mean Difference (Fixed) 95% CI0.01 [-0.35, 0.37]

02 Early exacerbations per patient
 FigureFigure 18. 02 Early exacerbations per patient
129Weighted Mean Difference (Fixed) 95% CI-0.21 [-0.55, 0.13]

03 Late exacerbations per patient
 FigureFigure 19. 03 Late exacerbations per patient
129Weighted Mean Difference (Fixed) 95% CI0.23 [-0.08, 0.54]

04 Patients with improvement in exacerbations
 FigureFigure 20. 04 Patients with improvement in exacerbations
129Peto Odds Ratio 95% CI1.48 [0.30, 7.42]

05 Patients with early improvements
 FigureFigure 21. 05 Patients with early improvements
129Peto Odds Ratio 95% CI1.65 [0.16, 17.49]

06 Patients with late improvements
 FigureFigure 22. 06 Patients with late improvements
129Peto Odds Ratio 95% CI1.26 [0.19, 8.43]

07 Early changes in lung function (% predicted FEV1)
 FigureFigure 23. 07 Early changes in lung function (% predicted FEV1)
129Weighted Mean Difference (Fixed) 95% CI2.90 [-14.14, 19.94]

08 Early changes in lung function (FEV1/FVC %)
 FigureFigure 24. 08 Early changes in lung function (FEV1/FVC %)
129Weighted Mean Difference (Fixed) 95% CI-0.90 [-12.02, 10.22]

09 Patients with increase in lung function (1 category)
 FigureFigure 25. 09 Patients with increase in lung function (1 category)
129Peto Odds Ratio 95% CI4.00 [0.68, 23.60]

10 Patients with a decrease in lung function
 FigureFigure 26. 10 Patients with a decrease in lung function
129Peto Odds Ratio 95% CI7.04 [0.66, 74.68]

11 Patients with adverse effects (new upper respiratory tract symptoms)
 FigureFigure 27. 11 Patients with adverse effects (new upper respiratory tract symptoms)
129Peto Odds Ratio 95% CI1.89 [0.45, 8.04]

12 Patients with early adverse effects
 FigureFigure 28. 12 Patients with early adverse effects
129Peto Odds Ratio 95% CI0.73 [0.16, 3.34]

13 Patients with late adverse effects
 FigureFigure 29. 13 Patients with late adverse effects
129Peto Odds Ratio 95% CI4.00 [0.68, 23.60]